|
Insider Trading: Xenoport Inc
Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Xenoport Inc in the last 24 months are illustrated in figures 1 and 2. Table 1 shows the monthly insider trading data of Xenoport Inc since year 2005. Table 2 shows the detailed insider transactions of Xenoport Inc since 2005.
The reporting company's ticker symbol is XNPT.
The reporting company's CIK number is 1130591.
The total value of stock buying since 2005 is $16,516,940.
The total value of stock sales is $20,455,751.
The total value of stock exercises is $599,070.
1 year stock price chart,
1 day stock price chart
opopp opopopop
Figure 1. Monthly insider transaction values at Xenoport Inc (XNPT) in the past 24 months.
The trade values of insider stock buys, sales, and option exercises are in logarithmic scale
as shown on the right axis labels.
The detailed monthly and daily insider transactions are listed in the 2 tables below.
08 09 10 11 12 01 2007 02 03 04 05 06 07 08 09 10 11 12 01 2008 02 03 04 05 06 07 -
Figure 2. Average prices of insider buys, sales, and option exercises at Xenoport Inc (XNPT) in the past 24 months. See table 2 for insider transaction details.
08 09 10 11 12 01 2007 02 03 04 05 06 07 08 09 10 11 12 01 2008 02 03 04 05 06 07 -
Table 1. Monthly summaries of insider stock purchases, sales, and option exercises
for Xenoport Inc (XNPT).
Trading Period
year-month |
Insider Buying
Shares Value ($) |
Insider Sales
Shares Value ($) |
Option Exercises
Shares Value ($) |
| 2008-07 | 0 | 0 | 5,000 | 192,576 | 1,000 | 1,500 |
| 2008-06 | 0 | 0 | 20,200 | 847,967 | 13,151 | 161,726 |
| 2008-05 | 353,333 | 14,994,123 | 20,492 | 878,394 | 0 | 0 |
| 2008-04 | 0 | 0 | 10,000 | 430,960 | 0 | 0 |
| 2008-03 | 29,634 | 1,240,458 | 0 | 0 | 0 | 0 |
| 2008-02 | 0 | 0 | 27,051 | 1,580,780 | 21,418 | 91,658 |
| 2008-01 | 0 | 0 | 24,402 | 1,428,424 | 0 | 0 |
| 2007-12 | 0 | 0 | 27,400 | 1,482,804 | 0 | 0 |
| 2007-11 | 0 | 0 | 28,829 | 1,494,353 | 0 | 0 |
| 2007-10 | 0 | 0 | 27,300 | 1,355,867 | 0 | 0 |
| 2007-09 | 0 | 0 | 19,000 | 830,550 | 0 | 0 |
| 2007-08 | 0 | 0 | 19,500 | 786,533 | 0 | 0 |
| 2007-07 | 0 | 0 | 21,583 | 986,156 | 0 | 0 |
| 2007-06 | 0 | 0 | 35,031 | 1,585,265 | 13,431 | 180,244 |
| 2007-05 | 0 | 0 | 48,570 | 2,029,225 | 5,000 | 7,500 |
| 2007-04 | 0 | 0 | 12,300 | 405,898 | 0 | 0 |
| 2007-03 | 0 | 0 | 36,952 | 918,432 | 11,192 | 150,196 |
| 2007-02 | 0 | 0 | 17,700 | 489,345 | 0 | 0 |
| 2007-01 | 0 | 0 | 15,300 | 376,519 | 0 | 0 |
| 2006-12 | 0 | 0 | 20,600 | 522,767 | 0 | 0 |
| 2006-11 | 306 | 6,112 | 13,900 | 331,023 | 0 | 0 |
| 2006-10 | 0 | 0 | 8,900 | 193,473 | 0 | 0 |
| 2006-09 | 0 | 0 | 5,910 | 128,438 | 0 | 0 |
| 2006-08 | 0 | 0 | 3,000 | 53,717 | 0 | 0 |
| 2006-07 | 0 | 0 | 3,000 | 57,858 | 0 | 0 |
| 2006-06 | 0 | 0 | 3,000 | 66,942 | 0 | 0 |
| 2006-05 | 0 | 0 | 3,000 | 67,560 | 0 | 0 |
| 2006-04 | 0 | 0 | 3,000 | 64,824 | 0 | 0 |
| 2006-03 | 0 | 0 | 3,000 | 58,172 | 0 | 0 |
| 2006-02 | 0 | 0 | 41,870 | 775,245 | 1,735 | 6,246 |
| 2006-01 | 0 | 0 | 2,000 | 35,684 | 0 | 0 |
| 2005-11 | 10,319 | 94,947 | 0 | 0 | 0 | 0 |
| 2005-09 | 13,200 | 181,300 | 0 | 0 | 0 | 0 |
Table 2. Detailed insider stock purchases, sales, and option exercises
for Xenoport Inc (XNPT)
| Trade Date |
Insider Name |
Trade Type |
Shares |
Price ($) |
Value ($) |
| 2008-07-14 | Gallop Mark A (SVP, Research) | Sale | 1,000 | 40.18 | 40,183 |
| 2008-07-01 | Harris William G (SVP, Finance and CFO) | Sale | 1,000 | 38.07 | 38,074 |
| 2008-07-01 | Gallop Mark A (SVP, Research) | Sale | 2,000 | 38.11 | 76,223 |
| 2008-07-01 | Cundy Kenneth C (SVP, Preclinical Development) | Sale | 1,000 | 38.10 | 38,096 |
| 2008-07-01 | Cundy Kenneth C (SVP, Preclinical Development) | Option Exercise | 1,000 | 1.50 | 1,500 |
| 2008-06-16 | Berns Paul L (Director) | Sale | 12,500 | 42.05 | 525,607 |
| 2008-06-16 | Berns Paul L (Director) | Option Exercise | 12,500 | 12.86 | 160,750 |
| 2008-06-02 | Harris William G (SVP, Finance and CFO) | Sale | 1,000 | 41.88 | 41,876 |
| 2008-06-02 | Gallop Mark A (SVP, Research) | Sale | 3,000 | 41.91 | 125,595 |
| 2008-06-02 | Cundy Kenneth C (SVP, Preclinical Development) | Sale | 1,000 | 41.88 | 41,882 |
| 2008-06-02 | Cundy Kenneth C (SVP, Preclinical Development) | Option Exercise | 651 | 1.50 | 976 |
| 2008-05-14 | Harris William G (SVP, Finance and CFO) | Sale | 500 | 45.06 | 22,530 |
| 2008-05-14 | Cundy Kenneth C (SVP, Preclinical Development) | Sale | 1,000 | 44.04 | 44,040 |
| 2008-05-13 | Freund John Gordon (Director) | Purchase | 97,000 | 43.59 | 4,228,065 |
| 2008-05-12 | Savello David R (SVP, Development) | Sale | 11,192 | 42.86 | 479,710 |
| 2008-05-12 | Freund John Gordon (Director) | Purchase | 147,008 | 43.23 | 6,354,773 |
| 2008-05-09 | Freund John Gordon (Director) | Purchase | 109,325 | 40.35 | 4,411,285 |
| 2008-05-01 | Harris William G (SVP, Finance and CFO) | Sale | 1,000 | 42.60 | 42,598 |
| 2008-05-01 | Gallop Mark A (SVP, Research) | Sale | 3,000 | 42.53 | 127,699 |
| 2008-05-01 | Cundy Kenneth C (SVP, Preclinical Development) | Sale | 1,000 | 42.61 | 42,614 |
| 2008-04-04 | Cundy Kenneth C (SVP, Preclinical Development) | Sale | 3,000 | 44.17 | 132,510 |
| 2008-04-01 | Harris William G (SVP, Finance and CFO) | Sale | 1,000 | 42.05 | 42,046 |
| 2008-04-01 | Gallop Mark A (SVP, Research) | Sale | 3,000 | 41.99 | 125,977 |
| 2008-04-01 | Cundy Kenneth C (SVP, Preclinical Development) | Sale | 1,000 | 42.09 | 42,087 |
| 2008-03-14 | Friedman Cathy (Director) | Purchase | 4,600 | 42.71 | 196,458 |
| 2008-03-14 | Freund John Gordon (Director) | Purchase | 15,156 | 41.60 | 630,514 |
| 2008-02-19 | Savello David R (SVP, Development) | Option Exercise | 4,168 | .00 | 0 |
| 2008-02-19 | Barrett Ronald W (Chief Executive Officer) | Sale | 8,000 | 54.57 | 435,411 |
| 2008-02-19 | Barrett Ronald W (Chief Executive Officer) | Option Exercise | 6,250 | .00 | 0 |
| 2008-02-19 | Harris William G (SVP, Finance and CFO) | Option Exercise | 834 | .00 | 0 |
| 2008-02-19 | Gallop Mark A (SVP, Research) | Option Exercise | 834 | .00 | 0 |
| 2008-02-19 | Cundy Kenneth C (SVP, Preclinical Development) | Option Exercise | 1,043 | .00 | 0 |
| 2008-02-19 | Rieflin William Jl (President) | Option Exercise | 1,459 | .00 | 0 |
| 2008-02-12 | Savello David R (SVP, Development) | Option Exercise | 6,830 | 13.42 | 91,658 |
| 2008-02-01 | Harris William G (SVP, Finance and CFO) | Sale | 1,500 | 61.75 | 92,629 |
| 2008-02-01 | Gallop Mark A (SVP, Research) | Sale | 4,000 | 61.75 | 246,984 |
| 2008-02-01 | Cundy Kenneth C (SVP, Preclinical Development) | Sale | 4,000 | 61.79 | 247,253 |
| 2008-01-16 | Barrett Ronald W (Chief Executive Officer) | Sale | 8,000 | 60.88 | 486,851 |
| 2008-01-02 | Harris William G (SVP, Finance and CFO) | Sale | 1,500 | 56.00 | 83,998 |
| 2008-01-02 | Gallop Mark A (SVP, Research) | Sale | 4,000 | 55.97 | 223,908 |
| 2008-01-02 | Cundy Kenneth C (SVP, Preclinical Development) | Sale | 4,000 | 56.01 | 224,078 |
| 2007-12-17 | Barrett Ronald W (Chief Executive Officer) | Sale | 8,000 | 54.55 | 435,914 |
| 2007-12-05 | Wierenga Wendall (Director) | Sale | 3,000 | 54.85 | 164,544 |
| 2007-12-03 | Harris William G (SVP, Finance and CFO) | Sale | 1,500 | 53.32 | 79,975 |
| 2007-12-03 | Cundy Kenneth C (SVP, Preclinical Development) | Sale | 4,000 | 53.41 | 212,870 |
| 2007-11-15 | Barrett Ronald W (Chief Executive Officer) | Sale | 8,000 | 54.28 | 434,039 |
| 2007-11-01 | Harris William G (SVP, Finance and CFO) | Sale | 1,500 | 49.45 | 74,179 |
| 2007-11-01 | Gallop Mark A (SVP, Research) | Sale | 3,000 | 49.52 | 148,194 |
| 2007-11-01 | Cundy Kenneth C (SVP, Preclinical Development) | Sale | 4,000 | 49.26 | 197,343 |
| 2007-10-15 | Barrett Ronald W (Chief Executive Officer) | Sale | 8,400 | 49.89 | 419,375 |
| 2007-10-01 | Harris William G (SVP, Finance and CFO) | Sale | 1,500 | 49.30 | 73,942 |
| 2007-10-01 | Gallop Mark A (SVP, Research) | Sale | 3,000 | 49.31 | 147,916 |
| 2007-10-01 | Cundy Kenneth C (SVP, Preclinical Development) | Sale | 4,000 | 49.28 | 197,049 |
| 2007-09-18 | Cundy Kenneth C (SVP, Preclinical Development) | Sale | 2,000 | 45.00 | 90,000 |
| 2007-09-17 | Barrett Ronald W (Chief Executive Officer) | Sale | 8,400 | 44.29 | 371,994 |
| 2007-09-04 | Gallop Mark A (SVP, Research) | Sale | 3,000 | 41.82 | 125,451 |
| 2007-09-04 | Cundy Kenneth C (SVP, Preclinical Development) | Sale | 2,000 | 41.84 | 83,678 |
| 2007-08-15 | Barrett Ronald W (Chief Executive Officer) | Sale | 8,400 | 39.38 | 330,814 |
| 2007-08-01 | Gallop Mark A (SVP, Research) | Sale | 3,000 | 43.04 | 129,128 |
| 2007-08-01 | Cundy Kenneth C (SVP, Preclinical Development) | Sale | 2,000 | 43.02 | 86,042 |
| 2007-07-16 | Barrett Ronald W (Chief Executive Officer) | Sale | 8,400 | 46.07 | 387,026 |
| 2007-07-03 | Cundy Kenneth C (SVP, Preclinical Development) | Sale | 2,000 | 45.00 | 90,000 |
| 2007-07-02 | Gallop Mark A (SVP, Research) | Sale | 3,000 | 44.82 | 134,465 |
| 2007-07-02 | Cundy Kenneth C (SVP, Preclinical Development) | Sale | 2,000 | 44.84 | 89,690 |
| 2007-06-15 | Barrett Ronald W (Chief Executive Officer) | Sale | 8,400 | 46.12 | 387,460 |
| 2007-06-04 | Savello David R (SVP, Development) | Sale | 13,431 | 44.44 | 596,813 |
| 2007-06-04 | Savello David R (SVP, Development) | Option Exercise | 13,431 | 13.42 | 180,244 |
| 2007-06-04 | Cundy Kenneth C (SVP, Preclinical Development) | Sale | 1,500 | 45.00 | 67,500 |
| 2007-06-01 | Gallop Mark A (SVP, Research) | Sale | 3,000 | 45.06 | 135,167 |
| 2007-06-01 | Cundy Kenneth C (SVP, Preclinical Development) | Sale | 2,500 | 45.02 | 112,542 |
| 2007-05-30 | Cundy Kenneth C (SVP, Preclinical Development) | Sale | 2,000 | 45.00 | 90,000 |
| 2007-05-22 | Cundy Kenneth C (SVP, Preclinical Development) | Sale | 5,000 | 42.91 | 214,549 |
| 2007-05-22 | Cundy Kenneth C (SVP, Preclinical Development) | Option Exercise | 5,000 | 1.50 | 7,500 |
| 2007-05-16 | Wierenga Wendall (Director) | Sale | 5,000 | 41.15 | 205,750 |
| 2007-05-15 | Barrett Ronald W (Chief Executive Officer) | Sale | 8,400 | 41.80 | 351,149 |
| 2007-05-15 | Nussbacher Kenneth J (Director) | Sale | 5,403 | 42.08 | 227,349 |
| 2007-05-14 | Gallop Mark A (SVP, Research) | Sale | 8,000 | 40.84 | 326,733 |
| 2007-05-14 | Nussbacher Kenneth J (Director) | Sale | 4,597 | 41.16 | 189,233 |
| 2007-05-10 | Roberts Bryan E (Director) | Sale | 70 | 41.11 | 2,877 |
| 2007-05-01 | Gallop Mark A (SVP, Research) | Sale | 3,000 | 41.68 | 125,040 |
| 2007-05-01 | Cundy Kenneth C (SVP, Preclinical Development) | Sale | 2,000 | 41.67 | 83,331 |
| 2007-04-26 | Cundy Kenneth C (SVP, Preclinical Development) | Sale | 100 | 44.24 | 4,424 |
| 2007-04-25 | Barrett Ronald W (Chief Executive Officer) | Sale | 2,700 | 38.12 | 102,935 |
| 2007-04-25 | Gallop Mark A (SVP, Research) | Sale | 1,000 | 38.26 | 38,264 |
| 2007-04-25 | Cundy Kenneth C (SVP, Preclinical Development) | Sale | 900 | 38.00 | 34,201 |
| 2007-04-16 | Barrett Ronald W (Chief Executive Officer) | Sale | 5,700 | 29.75 | 169,554 |
| 2007-03-22 | Savello David R (SVP, Development) | Option Exercise | 11,192 | 13.42 | 150,196 |
| 2007-03-22 | Barrett Ronald W (Chief Executive Officer) | Sale | 3,400 | 25.00 | 85,000 |
| 2007-03-15 | Barrett Ronald W (Chief Executive Officer) | Sale | 3,000 | 24.65 | 73,947 |
| 2007-03-14 | Harris William G (SVP, Finance and CFO) | Sale | 15,000 | 24.72 | 370,740 |
| 2007-03-09 | Gallop Mark A (SVP, Research) | Sale | 2,000 | 25.79 | 51,585 |
| 2007-03-01 | Gallop Mark A (SVP, Research) | Sale | 3,000 | 25.20 | 75,605 |
| 2007-03-01 | Cundy Kenneth C (SVP, Preclinical Development) | Sale | 1,000 | 25.20 | 25,201 |
| 2007-02-15 | Barrett Ronald W (Chief Executive Officer) | Sale | 5,700 | 28.25 | 160,910 |
| 2007-02-08 | Barrett Ronald W (Chief Executive Officer) | Sale | 2,700 | 30.00 | 81,000 |
| 2007-02-08 | Gallop Mark A (SVP, Research) | Sale | 1,000 | 30.00 | 30,000 |
| 2007-02-01 | Gallop Mark A (SVP, Research) | Sale | 3,000 | 24.01 | 72,042 |
| 2007-02-01 | Cundy Kenneth C (SVP, Preclinical Development) | Sale | 1,000 | 24.07 | 24,068 |
| 2007-01-16 | Barrett Ronald W (Chief Executive Officer) | Sale | 5,700 | 24.66 | 140,876 |
| 2007-01-03 | Gallop Mark A (SVP, Research) | Sale | 3,000 | 24.31 | 72,932 |
| 2007-01-03 | Cundy Kenneth C (SVP, Preclinical Development) | Sale | 1,000 | 24.30 | 24,296 |
| 2006-12-22 | Cundy Kenneth C (SVP, Preclinical Development) | Sale | 1,000 | 25.01 | 25,008 |
| 2006-12-15 | Barrett Ronald W (Chief Executive Officer) | Sale | 5,700 | 25.18 | 143,546 |
| 2006-12-15 | Wierenga Wendall (Director) | Sale | 4,000 | 25.02 | 100,080 |
| 2006-12-01 | Gallop Mark A (SVP, Research) | Sale | 3,000 | 26.09 | 78,141 |
| 2006-11-15 | Gallop Mark A (SVP, Research) | Purchase | 306 | 19.98 | 6,112 |
| 2006-11-06 | Wierenga Wendall (Director) | Sale | 5,000 | 23.91 | 119,540 |
| 2006-11-01 | Barrett Ronald W (Chief Executive Officer) | Sale | 3,000 | 23.78 | 71,347 |
| 2006-11-01 | Gallop Mark A (SVP, Research) | Sale | 3,000 | 23.77 | 71,257 |
| 2006-10-16 | Barrett Ronald W (Chief Executive Officer) | Sale | 3,000 | 23.88 | 71,655 |
| 2006-10-02 | Gallop Mark A (SVP, Research) | Sale | 3,000 | 20.57 | 61,933 |
| 2006-09-01 | Gallop Mark A (SVP, Research) | Sale | 3,000 | 21.75 | 65,198 |
| 2006-08-29 | Gallop Mark A (SVP, Research) | Sale | 1,000 | 20.02 | 20,015 |
| 2006-08-01 | Gallop Mark A (SVP, Research) | Sale | 2,000 | 16.85 | 33,702 |
| 2006-07-06 | Gallop Mark A (SVP, Research) | Sale | 1,000 | 20.00 | 20,000 |
| 2006-07-03 | Gallop Mark A (SVP, Research) | Sale | 2,000 | 18.93 | 37,858 |
| 2006-06-01 | Gallop Mark A (SVP, Research) | Sale | 3,000 | 22.31 | 66,942 |
| 2006-05-01 | Gallop Mark A (SVP, Research) | Sale | 3,000 | 22.52 | 67,560 |
| 2006-04-03 | Gallop Mark A (SVP, Research) | Sale | 3,000 | 21.61 | 64,824 |
| 2006-03-15 | Gallop Mark A (SVP, Research) | Sale | 1,000 | 20.02 | 20,020 |
| 2006-03-01 | Gallop Mark A (SVP, Research) | Sale | 2,000 | 19.08 | 38,152 |
| 2006-02-24 | Harris William G (SVP, Finance and CFO) | Sale | 22,000 | 18.62 | 407,584 |
| 2006-02-15 | Tollefson Gary D (Director) | Option Exercise | 1,735 | 3.60 | 6,246 |
| 2006-01-03 | Gallop Mark A (SVP, Research) | Sale | 2,000 | 17.84 | 35,684 |
| 2005-11-28 | Cundy Kenneth C (SVP, Preclinical Development) | Purchase | 700 | 13.00 | 9,100 |
| 2005-11-16 | Barrett Ronald W (Chief Executive Officer) | Purchase | 2,380 | 8.92 | 21,241 |
| 2005-11-16 | Dower William J (VP, Discovery Biology) | Purchase | 1,540 | 8.92 | 13,744 |
| 2005-11-16 | Gallop Mark A (SVP, Research) | Purchase | 1,733 | 8.92 | 15,467 |
| 2005-11-16 | Cundy Kenneth C (SVP, Preclinical Development) | Purchase | 1,694 | 8.92 | 15,118 |
| 2005-11-16 | Rieflin William Jl (President) | Purchase | 2,272 | 8.92 | 20,277 |
| 2005-09-13 | Freund John Gordon (Director) | Purchase | 4,200 | 15.11 | 63,478 |
| 2005-09-07 | Freund John Gordon (Director) | Purchase | 7,480 | 13.11 | 98,062 |
| 2005-09-06 | Freund John Gordon (Director) | Purchase | 1,520 | 13.00 | 19,760 |
Insider trading activities including stock purchases, stock sales, and option exercises
listed in the above tables cannot be completely guaranteed as to their accuracy.
For more insider trading information of Xenoport Inc (symbol XNPT,
CIK number 1130591) see
the Securities and Exchange Commission (SEC) website.
|
|
